Experimental CAR T-Cell therapy targets tough blood cancers
NCT ID NCT03938987
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized cell therapy called CAR T-cells for people with relapsed or hard-to-treat lymphoma or acute lymphoblastic leukemia (ALL). The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back. The trial aims to find the best dose and evaluate safety and effectiveness in 63 participants aged 2 to 70.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR T-cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat lymphoma or leukemia.
What could go wrong
This is an early-phase trial with only 63 participants, so results may not apply to everyone. Side effects can be serious, including immune reactions and nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alberta Children's Hospital
NOT_YET_RECRUITINGCalgary, Alberta, T3B6A8, Canada
Contact
-
Cross Cancer Institute
RECRUITINGEdmonton, Alberta, T6G1Z2, Canada
Contact
-
Foothills Medical Centre
NOT_YET_RECRUITINGCalgary, Alberta, T2N2T9, Canada
Contact
-
Stollery Children's Hospital
NOT_YET_RECRUITINGEdmonton, Alberta, T6G2B7, Canada
Contact
-
Tom Baker Cancer Centre
NOT_YET_RECRUITINGCalgary, Alberta, T2N4N2, Canada
Contact
-
University of Alberta Hospital
RECRUITINGEdmonton, Alberta, T6G2B7, Canada
Contact